British Patient Capital
VC Fund
Sheffield, United Kingdom
British Patient Capital is a VC fund in Sheffield focused on Biotechnology and Health Care. British Patient Capital invests in a diversified portfolio of best-in-class venture and growth capital funds and start ups, capturing value through financing the growth of innovative companies. We invest on a commercial basis to deliver competitive returns and manage risk.As well as providing our own funding we work to encourage more investors tomake allocations to this asset class by demonstrating that a long-term patient capital investment strategy can produce commercially attractive returns.Once we’ve established a strong record, and have proved the value of the asset class, we intend to privatise British Patient Capital at an appropriate time in the future.
- Total investments:
- 39
- Last investment:
- Lead investor:
- 23%
Last updated:
For AI agents: llms.txt
Industries British Patient Capital invests in
Stages British Patient Capital invests in
Countries British Patient Capital invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Alexandra Woodman
|
|||
Chloe Hall
|
|||
Carmine Circelli
|
|||
Emma Johnson
|
|||
| See all 9 contacts → | |||
Investment Focus
Industry
- Biotechnology 13 (33%)
- Health Care 7 (18%)
- Life Science 6 (15%)
- Therapeutics 5 (13%)
- FinTech 4 (10%)
Stage
- Series B 11 (28%)
- Series C 9 (23%)
- Series A 6 (15%)
- Venture - Series Unknown 4 (10%)
- Series D 3 (8%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Alexandra Woodman
Investment Analyst
|
Investment Analyst | Total investments: 0 | Find email | |
|
Chloe Hall
Investment Manager
|
Investment Manager | Total investments: 0 | Find email | |
Peter Keen
Independent Investment Committee Member
|
Independent Investment Committee Member | Total investments: 4 | Find email | |
|
Carmine Circelli
Senior Investment Manager
|
Senior Investment Manager | Total investments: 3 | Find email | |
|
Emma Johnson
Investment Manager
|
Investment Manager | Total investments: 4 | Find email | |
| See all 9 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Paragraf
|
Paragraf is the world’s leading graphene-based electronic device design, development and manufacturing company. Building on our proprietary process to grow graphene directly on standard semiconductor industry substrates, Paragraf has pioneered the delivery of two-dimensional technologies at scale. Paragraf’s high-quality graphene – integratablewith standard semiconductor tool process lines – has unlocked the incorporation of this remarkable material into both existing and new electronic devices and applications. Through our world-first dedicated graphene device foundry, Paragraf delivers high-performance, low-power technologies to multiple markets and offers two-dimensional-material foundry services to customers and partners, providing graphene in chips to their device requirements. | $55M / Series C / Aug 25, 2025 | |
Maxion Therapeutics
|
Maxion Therapeutics helps in learning transformative therapies. It uses this technology to deliver long-acting, safe, and effective medications against previously inaccessible targets. | $75.3M / Series A / Mar 17, 2025 | |
Quantexa
|
Quantexa’s Contextual Decision Intelligence is a new approach to data that gives organizations the ability to connect internal and external data sets to provide a single view, enriched with intelligence about the relationships between people, places and organizations. Our platform dynamically generates the context needed to automate millions ofoperational decisions, at scale, across multiple business units, including Anti-Money Laundering, Know-Your-Customer, Fraud, Credit Risk and Customer Intelligence. Quantexa is a global business with offices in London, New York, Boston, Brussels, Toronto, Singapore, Melbourne and Sydney. | $175M / Series F / Mar 05, 2025 | |
Cambridge GaN Devices
|
Cambridge GaN Devices develops transistors designed to bring widespread adoption of GaN technology in consumer electronics. | $32M / Series C / Feb 18, 2025 | |
Tenpoint Therapeutics
|
Tenpoint Therapeutics is a biotechnology company pursuing vision-restoring engineered cell-based therapeutics. | Venture - Series Unknown / Dec 11, 2024 | |
Tokamak Energy
|
Tokamak Energy is a private company developing and accelerating the development of fusion power. It requires scientific thinking and knowledge, specialist expertise and serious determination. The company offers the smallest and most cost-effective solution. Their unique approach is centred on rapid innovation using the latest materials andtechnology but building on decades of scientific research and experience. Tokamak Energy focused on spherical tokamaks, pioneered at Culham because these compact devices can achieve a much higher plasma pressure for a given magnetic field than conventional tokamaks. They deploying high-temperature superconducting magnets to control the plasma within its devices. These allow high magnetic fields to be created in the confined dimensions of compact tokamaks, further improving the efficiency of the device.Tokamak Energy was founded in 2009 and is headquartered in Oxfordshire, United Kingdom. | $125M / Venture - Series Unknown / Nov 19, 2024 | |
Nuclera
|
Nuclera offers a protein prototyping system to accelerate drug discovery by making proteins readily available to researchers. Nuclera's eProtein DiscoveryTM system allows scientists to rapidly produce and test proteins for drug discovery. | $75M / Series C / Oct 15, 2024 | |
Purespring Therapeutics
|
Purespring Therapeutics is an AAV gene therapy company focused on the kidney globally. | $104.5M / Series B / Oct 09, 2024 | |
Form3
|
Form3 delivers cloud-based connectivity, payment processing, clearing, and settlement services. It is a fully managed payment technology service combining a powerful AWS cloud processing platform, multiple-scheme payment gateways, and a fully managed 24x7 service model. Form3's powerful micro-services architecture and API's provide asingle point of simple access to the full universe of payment schemes.Its clients include a wide range of regulated financial institutions, including leading banks, non-bank financial institutions, and fintech companies (payment institutions, e-money providers, and pre-paid card providers). Form3 was founded in 2016 and is based in London, England. | $60.2M / Series C / Sep 10, 2024 | |
Epsilogen
|
IGEM Therapeutics is a developer of an immuno-oncology company intended to develop immunoglobulin antibodies to treat cancer.The company's offerings include IgE-based drugs targeting solid tumors, enabling patients to kill parasites which reside in human tissue, also the home of the solid tumor. | $16.3M / Series B / Sep 09, 2024 | |
| See all 39 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does British Patient Capital invest in?
British Patient Capital invests primarily in Biotechnology, Health Care and Life Science startups, most often at Series B and Series C stage. Most of the 39 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact British Patient Capital?
Public channels for British Patient Capital include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at British Patient Capital?
The team at British Patient Capital includes Alexandra Woodman (Investment Analyst), Chloe Hall (Investment Manager) and Peter Keen (Independent Investment Committee Member), among 9 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
